Pages that link to "Q48340234"

The following pages link to Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial (Q48340234):

Displaying 28 items.

• Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia (Q36816685) (← links)
• Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives (Q37712353) (← links)
• Management of elderly patients with acute promyelocytic leukemia: progress and problems (Q38108471) (← links)
• Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia (Q38109541) (← links)
• What is the standard regimen for patients with acute promyelocytic leukemia? (Q38204310) (← links)
• Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction (Q38221006) (← links)
• Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years (Q38232465) (← links)
• Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. (Q38256888) (← links)
• Current standard treatment of adult acute promyelocytic leukaemia (Q38674575) (← links)
• Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma (Q38779589) (← links)
• Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis (Q38798789) (← links)
• Current management of newly diagnosed acute promyelocytic leukemia (Q38809825) (← links)
• Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide (Q38891536) (← links)
• Non-inferiority trials: No better? No worse? No change? No pain? (Q39096602) (← links)
• Incidence and outcomes for adults diagnosed with acute myeloid leukemia in the north of England: a real world study (Q41051992) (← links)
• Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial (Q41347785) (← links)
• Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines (Q48346019) (← links)
• Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada (Q51032738) (← links)
• Economic evaluation of arsenic trioxide compared to all-trans retinoic acid conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada (Q51039141) (← links)
• [The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients]. (Q53483035) (← links)
• Zielgerichtete Therapien bei hämatologischen Erkrankungen (Q58023753) (← links)
• Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet (Q64053212) (← links)
• The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial (Q87366126) (← links)
• [How I treat PML-RARα positive actue promyelocytic leukemia] (Q88089968) (← links)
• [Clinical features and prognostic analysis of high-risk acute promyelocytic leukemia patients] (Q89257239) (← links)
• Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia (Q89777348) (← links)
• Current first- and second-line treatment options in acute promyelocytic leukemia (Q92158117) (← links)
• Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer (Q99710858) (← links)